KNSA Q3'26 Earnings Preview: EPS Estimate 0.37 USD
Kiniksa Pharmaceuticals is set to report Q3'26 results on October 27 before the market opens. Revenue is estimated at 260.66 million USD, with EPS anticipated at 0.37 USD.
Kiniksa Pharmaceuticals is set to report Q3'26 results on October 27 before the market opens. Revenue is estimated at 260.66 million USD, with EPS anticipated at 0.37 USD.